Supplementary table S1.

Summary of groups and outcomes after experimental infection with Ab4 or Ab4ΔORF2 nine-months prior to this experimental EHV-1 Ab4 challenge infection [a].

	Control	**Ab4ΔORF2**	**Ab4**
Infection	Not infected	Ab4ΔORF2 [b]	Ab4 [b]
Horses (n)	8 per group		
Sex	4 mares and 4 geldings per group		
Age, median (range)	2 (2-3 years)	3 (2-4 years)	3 (2-3 years)
Fever (>38.5°C)	none	Reduced initial fever	Fever peak 36-60 h pi [c]
Clinical signs	none	Mild respiratory disease	
Nasal virus shedding [d]	none	7/8 horses, lower viral amounts than in Ab4 group	7/8 horses
Cell-associated viremia [e]	none	All horses, similar in both groups	
Intranasal immunity [f]	none	Intranasal antibody response	
Systemic antibody response [f]	none	Strong systemic antibody response	
Systemic cellular response [g]	none	Undetectable T cell response	

[a] Full description in Schnabel *et al.*, 2018, BMC Vet Res; https://doi.org/10.1186/s12917-018-1563-4

[b] Horses were infected intransally with $1x10^7$ plaque forming units (PFU)

[c] pi = post infection

[d] measured by virus isolation

[e] analyzed by real-time PCR in PBMC using the EHV-1 gB gene

[f] EHV-1 gB, gC, and gD-specific antibody quantification using a fluorescent bead-based multiplex assay

[g] evaluated by flow cytometric analysis of IFN-γ producing T-cells in PBMC after re-stimulation with EHV-1 *in vitro*